Regenerative neuropathy treatment at Regenerve in St. Louis goes after three things that keep a damaged nerve hurting. We calm the inflammation around the nerve. We quiet the irritated C-fibers that fire on their own. And we let the dorsal root ganglion, the relay that sets the nerve’s volume, settle back down. Testing decides which of the three leads.
What does “regenerative” mean for a nerve that hurts?
Most neuropathy care treats the pain as a signal to be turned down from the top. A pill dulls the reading of it in the spinal cord and brain, and the nerve keeps shouting. Regenerative care works at the other end. It changes the conditions the nerve lives in, so the nerve behaves differently.
Think of a smoke alarm with a frayed wire. You can pull the battery, and the house goes quiet while the wire keeps sparking. Or you can stop the sparking, clear the smoke, and reset the panel. Those three jobs are the three targets on this page.
That is not a philosophy. It comes from what the nerve itself does. In fourteen patients with burning feet from nerve injury or polyneuropathy, a numbing block placed on the nerve below the knee wiped out the pain completely in every one of them, within a median of ten minutes. The drug levels in the blood were too low to act on the brain. The authors concluded that input from the nerve is what keeps neuropathic pain going [1]. Quiet the input, and the pain goes with it.
Why does an injured nerve keep firing?
The small, slow pain fibers are called C-fibers. In a healthy foot they fire when something is actually hot or sharp. In a painful neuropathy many of them fire with nothing touching the skin at all.
Researchers recorded single C-fibers through a fine needle in 19 people with polyneuropathy. In the 11 who had burning pain, 40.5 percent of the pain fibers were firing on their own or were over-sensitized. In the 8 whose neuropathy did not hurt, it was 14.6 percent. The difference sat mostly in fibers that are normally silent [2]. In people with type 2 diabetes and painful neuropathy, 72 percent of the recorded pain fibers were spontaneously active, against 15 percent in diabetic neuropathy without pain [3].
So the burning at 2 a.m. is not imagined, and it is not the nerve “dying.” It is a fiber that has lost its off switch.
What is feeding the inflammation around the nerve?
A nerve sits in tissue, and that tissue can be inflamed. When it is, it releases cytokines, chemokines and lipid signals. Those chemicals sensitize and stimulate pain fibers, and over time they promote the long-term rewiring that keeps neuropathic pain going [4].
Here is the part a standard visit misses: much of that inflammation is made by your metabolism. The same study followed the chemistry in diabetic mice. Their overactive pain fibers reacted more strongly to methylglyoxal, a sugar by-product, through a pain channel the fibers had already sensitized [3]. Insulin does something similar. In mouse sensory neurons, insulin turned up the response of the capsaicin (heat-and-pain) channel at the ganglion itself. Blocking the insulin receptor took that boost away [5].
That is metainflammation, the slow chemical fire of insulin resistance, reaching all the way down to the nerve. For years I told patients with pre-diabetes that their A1c was fine. Their nerves did not agree. Now we test insulin, not just sugar, because a nerve that is soaking in it will keep firing no matter what we inject. See why neuropathy often shows up before a diabetes diagnosis and how sugar damages nerves.
What is the dorsal root ganglion, and why reprogram it?
Every sensory nerve in your leg has its cell bodies in a small cluster just outside the spine. That cluster is the dorsal root ganglion, or DRG. It used to be described as a passive support station. A 2014 review of the anatomy and physiology concluded instead that the DRG is as involved in generating neuropathic pain as the nerve ending and the spinal cord [6].
The clearest proof is phantom limb pain, the pain of a foot that is no longer there. In 31 amputees, numbing medicine placed at the DRG shut off the phantom pain quickly and reversibly. It worked even at a dilution too weak to block signals coming from farther down the nerve. The researchers concluded the pain was generated in the ganglion itself [7].
The ganglion learns. Months of irritated input turn its gain up, and it starts producing pain on its own. Our position is that the gain can be turned back down. Calm the tissue, quiet the fibers, and keep that input low long enough, and the ganglion resets its settings. That is what we mean by reprogramming the DRG.
How do you find which target to treat first?
Neuropathy is not one disease, so the first visit is a measurement, not a menu. When 902 people with nerve pain had the same standardized sensory testing, they split into three distinct profiles. A third had the “irritable nociceptor” pattern: sensation preserved, but heat and cold hurt too much. Others had mostly loss of sensation [8]. Those profiles respond to different treatments.
Our workup is done at the St. Louis clinic:
- EMG and nerve conduction testing on site, to show which nerves are hurt and where along them
- Skin biopsy when the small C-fibers are the suspect and large-fiber testing comes back normal
- Metabolic labs that look at insulin, not only A1c
- VNG balance testing when unsteadiness may not be the feet alone
- A hands-on exam for an entrapped nerve, which needs a different plan from a metabolic one
The full sequence is laid out in our neuropathy workup.
Which treatments act on each target?
The inflamed tissue around the nerve. Orthobiologic injections, platelet-rich plasma (PRP) or bone marrow concentrate placed along the nerve under ultrasound, deliver concentrated signaling proteins from your own blood to the tissue that is inflamed. In a randomized trial at Assiut University Hospital in Egypt, 60 adults with type 2 diabetes and neuropathy got either ultrasound-guided PRP around the nerve plus their usual medical treatment, or medical treatment alone. Pain, numbness and a standard nerve score improved more in the PRP group at one, three and six months [9]. Palmitoylethanolamide (PEA) and exosome-based support work on the same target. So does the metabolic plan, which shuts off the supply line.
The irritated C-fibers. The Qutenza 8 percent capsaicin patch is applied in the office. It works by defunctionalizing the overactive pain-fiber endings in the skin, and one application has relieved neuropathic pain for up to 12 weeks [10]. Class 4 laser aims at the energy machinery of stressed nerve tissue and the small vessels that feed it.
The ganglion and the circuit above it. Every quiet day at the first two targets is a day the DRG is not being trained to amplify. When the circuit still runs hot, neuromodulation is next, starting with the NS100 vagal stimulation course and peripheral nerve stimulation. These are all on our services page.
No one gets all of it. The plan is the smallest set that covers the targets your testing found, and existing prescriptions change only with your physician.
What does the metabolic part ask of you?
This is where I will be blunt, because the people who get better here are the ones who hear it. You’re probably going to call me an asshole for this part. You’re not going to like me in the process, but you’re going to like me at the end. If the insulin and the sugar by-products are still pouring into the tissue, every injection is bailing water from a boat that is still taking it on.
So the plan includes food built around protein and fewer acellular carbohydrates, movement your feet can tolerate, and sleep. Those are not aftercare. They are the treatment for the first target, and they are the part you control. The office procedures buy the quiet. Your metabolism decides whether it lasts.
Is regenerative neuropathy treatment worth trying if pills have not worked?
Pills that turn the signal down centrally, such as gabapentin, pregabalin and duloxetine, help some people and leave many with side effects and the same burning feet. That does not mean the nerve is out of options. It means the treatment was aimed at the wrong end of the circuit. A measured workup tells you which end is driving your pain. That is a better place to start than a fourth prescription.
Questions patients ask about regenerative neuropathy treatment
Does insurance cover regenerative neuropathy treatment?
Parts of it often are. Nerve testing and many office treatments are billed to insurance when they are medically necessary. PRP and other orthobiologic injections are non-covered services. We verify your benefits before anything is scheduled. See insurance and coverage questions for neuropathy care.
Do I have to stop gabapentin or duloxetine before starting?
No. Nothing you take is stopped on day one. As the inflammation, the C-fibers and the ganglion quiet down, your physician decides with you whether a dose can come down. See what the evidence shows for gabapentin and pregabalin.
My feet are numb, not painful. Does this apply to me?
Yes, and numbness deserves the workup more, not less. Numbness usually means signals are failing, and it raises the risk of falls and foot wounds. Testing shows which fibers are involved and what is driving it. See when numb feet should be evaluated.
Do you see patients from Illinois?
Yes. Our clinic is in St. Louis, minutes from Lambert International Airport, and many of our neuropathy patients drive in from the Illinois side. See neuropathy treatment for Illinois patients.
The information on this page is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician.
Sources
- Haroutounian S, Nikolajsen L, Bendtsen TF, Finnerup NB, Kristensen AD, Hasselstrøm JB, Jensen TS. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain. 2014;155(7):1272-1279. doi:10.1016/j.pain.2014.03.022 (PMID 24704366)
- Kleggetveit IP, Namer B, Schmidt R, Helås T, Rückel M, Ørstavik K, Schmelz M, Jørum E. High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain. 2012;153(10):2040-2047. doi:10.1016/j.pain.2012.05.017 (PMID 22986070)
- Becker AK, Babes A, Düll MM, Khalil M, Kender Z, Gröner J, Namer B, Reeh PW, Sauer SK. Spontaneous activity of specific C-nociceptor subtypes from diabetic patients and mice: involvement of reactive dicarbonyl compounds and (sensitized) transient receptor potential channel A1. J Peripher Nerv Syst. 2023;28(2):202-225. doi:10.1111/jns.12546 (PMID 37029502)
- Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26-37. doi:10.1093/bja/aet128 (PMID 23794642)
- Hori A, Hotta N, Fukazawa A, Estrada JA, Katanosaka K, Mizumura K, et al. Insulin potentiates the response to capsaicin in dorsal root ganglion neurons in vitro and muscle afferents ex vivo in normal healthy rodents. J Physiol. 2022;600(3):531-545. doi:10.1113/JP282740 (PMID 34967443)
- Krames ES. The role of the dorsal root ganglion in the development of neuropathic pain. Pain Med. 2014;15(10):1669-1685. doi:10.1111/pme.12413 (PMID 24641192)
- Vaso A, Adahan HM, Gjika A, Zahaj S, Zhurda T, Vyshka G, Devor M. Peripheral nervous system origin of phantom limb pain. Pain. 2014;155(7):1384-1391. doi:10.1016/j.pain.2014.04.018 (PMID 24769187)
- Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017;158(2):261-272. doi:10.1097/j.pain.0000000000000753 (PMID 27893485)
- Hassanien M, Elawamy A, Kamel EZ, Khalifa WA, Abolfadl GM, Roushdy ASI, et al. Perineural platelet-rich plasma for diabetic neuropathic pain, could it make a difference? Pain Med. 2020;21(4):757-765. doi:10.1093/pm/pnz140 (PMID 31298289)
- Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490-502. doi:10.1093/bja/aer260 (PMID 21852280)
